Copyright Reports & Markets. All rights reserved.

Global Drug-Resistant Tuberculosis Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Drug-Resistant Tuberculosis Treatment
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Drug-Resistant Tuberculosis Treatment by Type
    • 1.3.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Type in 2022
    • 1.3.3 First-Line Anti-TB Drugs
    • 1.3.4 Second-Line Anti-TB Drugs
    • 1.3.5 Others
  • 1.4 Global Drug-Resistant Tuberculosis Treatment Market by Application
    • 1.4.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospital Pharmacy
    • 1.4.3 Online Pharmacy
    • 1.4.4 Retail Pharmacy
    • 1.4.5 Others
  • 1.5 Global Drug-Resistant Tuberculosis Treatment Market Size & Forecast
  • 1.6 Global Drug-Resistant Tuberculosis Treatment Market Size and Forecast by Region
    • 1.6.1 Global Drug-Resistant Tuberculosis Treatment Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Drug-Resistant Tuberculosis Treatment Market Size by Region, (2018-2029)
    • 1.6.3 North America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
    • 1.6.6 South America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Sanofi
    • 2.1.1 Sanofi Details
    • 2.1.2 Sanofi Major Business
    • 2.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.1.4 Sanofi Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Sanofi Recent Developments and Future Plans
  • 2.2 Novartis AG
    • 2.2.1 Novartis AG Details
    • 2.2.2 Novartis AG Major Business
    • 2.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.2.4 Novartis AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Novartis AG Recent Developments and Future Plans
  • 2.3 Endo International plc
    • 2.3.1 Endo International plc Details
    • 2.3.2 Endo International plc Major Business
    • 2.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.3.4 Endo International plc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Endo International plc Recent Developments and Future Plans
  • 2.4 CMP Pharma
    • 2.4.1 CMP Pharma Details
    • 2.4.2 CMP Pharma Major Business
    • 2.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.4.4 CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 CMP Pharma Recent Developments and Future Plans
  • 2.5 STI Pharma LLC
    • 2.5.1 STI Pharma LLC Details
    • 2.5.2 STI Pharma LLC Major Business
    • 2.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.5.4 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 STI Pharma LLC Recent Developments and Future Plans
  • 2.6 Akorn Incorporated
    • 2.6.1 Akorn Incorporated Details
    • 2.6.2 Akorn Incorporated Major Business
    • 2.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.6.4 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Akorn Incorporated Recent Developments and Future Plans
  • 2.7 Lupin
    • 2.7.1 Lupin Details
    • 2.7.2 Lupin Major Business
    • 2.7.3 Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.7.4 Lupin Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Lupin Recent Developments and Future Plans
  • 2.8 Johnson & Johnson Services Inc.
    • 2.8.1 Johnson & Johnson Services Inc. Details
    • 2.8.2 Johnson & Johnson Services Inc. Major Business
    • 2.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.8.4 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Johnson & Johnson Services Inc. Recent Developments and Future Plans
  • 2.9 Macleods Pharmaceuticals Ltd
    • 2.9.1 Macleods Pharmaceuticals Ltd Details
    • 2.9.2 Macleods Pharmaceuticals Ltd Major Business
    • 2.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.9.4 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
  • 2.10 Pfizer Inc
    • 2.10.1 Pfizer Inc Details
    • 2.10.2 Pfizer Inc Major Business
    • 2.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.10.4 Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Pfizer Inc Recent Developments and Future Plans
  • 2.11 Hikma Pharmaceuticals PLC
    • 2.11.1 Hikma Pharmaceuticals PLC Details
    • 2.11.2 Hikma Pharmaceuticals PLC Major Business
    • 2.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.11.4 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Hikma Pharmaceuticals PLC Recent Developments and Future Plans
  • 2.12 Lannett
    • 2.12.1 Lannett Details
    • 2.12.2 Lannett Major Business
    • 2.12.3 Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.12.4 Lannett Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Lannett Recent Developments and Future Plans
  • 2.13 Mylan N.V.
    • 2.13.1 Mylan N.V. Details
    • 2.13.2 Mylan N.V. Major Business
    • 2.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.13.4 Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Mylan N.V. Recent Developments and Future Plans
  • 2.14 Teva Pharmaceutical Industries Ltd
    • 2.14.1 Teva Pharmaceutical Industries Ltd Details
    • 2.14.2 Teva Pharmaceutical Industries Ltd Major Business
    • 2.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.14.4 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
  • 2.15 Fresenius Kabi AG
    • 2.15.1 Fresenius Kabi AG Details
    • 2.15.2 Fresenius Kabi AG Major Business
    • 2.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
    • 2.15.4 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 Fresenius Kabi AG Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Drug-Resistant Tuberculosis Treatment Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Drug-Resistant Tuberculosis Treatment by Company Revenue
    • 3.2.2 Top 3 Drug-Resistant Tuberculosis Treatment Players Market Share in 2022
    • 3.2.3 Top 6 Drug-Resistant Tuberculosis Treatment Players Market Share in 2022
  • 3.3 Drug-Resistant Tuberculosis Treatment Market: Overall Company Footprint Analysis
    • 3.3.1 Drug-Resistant Tuberculosis Treatment Market: Region Footprint
    • 3.3.2 Drug-Resistant Tuberculosis Treatment Market: Company Product Type Footprint
    • 3.3.3 Drug-Resistant Tuberculosis Treatment Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Drug-Resistant Tuberculosis Treatment Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Drug-Resistant Tuberculosis Treatment Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
  • 6.2 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
  • 6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country
    • 6.3.1 North America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2029)
    • 6.3.2 United States Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
  • 7.2 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
  • 7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country
    • 7.3.1 Europe Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 7.3.3 France Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region
    • 8.3.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Consumption Value by Region (2018-2029)
    • 8.3.2 China Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 8.3.5 India Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
  • 9.2 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
  • 9.3 South America Drug-Resistant Tuberculosis Treatment Market Size by Country
    • 9.3.1 South America Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country
    • 10.3.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Drug-Resistant Tuberculosis Treatment Market Drivers
  • 11.2 Drug-Resistant Tuberculosis Treatment Market Restraints
  • 11.3 Drug-Resistant Tuberculosis Treatment Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Drug-Resistant Tuberculosis Treatment Industry Chain
  • 12.2 Drug-Resistant Tuberculosis Treatment Upstream Analysis
  • 12.3 Drug-Resistant Tuberculosis Treatment Midstream Analysis
  • 12.4 Drug-Resistant Tuberculosis Treatment Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Drug-Resistant Tuberculosis Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    This report is a detailed and comprehensive analysis for global Drug-Resistant Tuberculosis Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Drug-Resistant Tuberculosis Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Drug-Resistant Tuberculosis Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Drug-Resistant Tuberculosis Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Drug-Resistant Tuberculosis Treatment market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Drug-Resistant Tuberculosis Treatment
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Drug-Resistant Tuberculosis Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Novartis AG, Endo International plc, CMP Pharma and STI Pharma LLC, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Drug-Resistant Tuberculosis Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    First-Line Anti-TB Drugs
    Second-Line Anti-TB Drugs
    Others
    Market segment by Application
    Hospital Pharmacy
    Online Pharmacy
    Retail Pharmacy
    Others
    Market segment by players, this report covers
    Sanofi
    Novartis AG
    Endo International plc
    CMP Pharma
    STI Pharma LLC
    Akorn Incorporated
    Lupin
    Johnson & Johnson Services Inc.
    Macleods Pharmaceuticals Ltd
    Pfizer Inc
    Hikma Pharmaceuticals PLC
    Lannett
    Mylan N.V.
    Teva Pharmaceutical Industries Ltd
    Fresenius Kabi AG
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Drug-Resistant Tuberculosis Treatment product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Drug-Resistant Tuberculosis Treatment, with revenue, gross margin and global market share of Drug-Resistant Tuberculosis Treatment from 2018 to 2023.
    Chapter 3, the Drug-Resistant Tuberculosis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Drug-Resistant Tuberculosis Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Drug-Resistant Tuberculosis Treatment.
    Chapter 13, to describe Drug-Resistant Tuberculosis Treatment research findings and conclusion.

    Buy now